These hybrid mutations are found in up to 4% of ATC and 9% of poor differentiated thyroid cancer [33]and lead to continuous activation of proliferating MAPK pathway through MEK activation [34] (Fig. 1). The gene discussed is MAP2K7; the disease is thyroid cancer.